AlphaGalileo is a service for the media.
Journalists should register for free access to embargoed
news and press office contact information.
Please register view details
Please register to view contact details
Please log in or register to view articles older than 3 months
This item is under embargo and is only visible to journalists
Bookmark this item in My Area
This item is bookmarked
Add comments to this news release
In a paper to be published in the New Year, Dr Cutler, an expert in the antimicrobial properties of plant extracts, claims that allicin - a compound that occurs naturally in garlic – kills not only established varieties of MRSA, but also destroys the new generation of ‘super-superbugs’ that have evolved resistance to Vancomycin and Glycopeptides, the powerful antibiotics widely considered to be the last line of defence against MRSA.
MRSA (Methicillin-resistant Staphylococcus aureus) now causes an estimated 2,000 deaths in UK hospitals each year mainly through secondary infection of surgical wounds. Though MRSA organisms can live harmlessly in humans and are carried in the nasal passages and on the skin, they can cause fatal infection in immune-suppressed patients, the elderly, the young and those with surgical implants.
Doctors have become increasingly alarmed over the past few months by the emergence in UK hospitals of new generations of resistant strains of MRSA known as VISAs, and GISAs (Vancomycin or Glycopeptide resistant Staphylococcus aureus). MRSA has also become endemic in many hospitals, especially in London and the South-East, prompting the NHS to review its hygiene procedures.
Dr Cutler, recently proved that allicin destroys the MRSA microbe in laboratory trials, has now teamed up with a new company, Allicin International, to develop topical treatments to prevent MRSA infection. The group have developed a nasal cream, oral capsules and soaps that have proved effective against both MRSA and GISA.
In partnership with colleagues in the NHS, Dr Cutler is now embarking on a major clinical trial involving around two hundred volunteers, including patients at several hospitals in London and the South East.
Dr Cutler said: "The trials we have conducted so far show that this formulation is highly effective against MRSA, and it could save many lives. This finding is backed up by initial findings a number of recent case studies. We have been trying to set up a clinical trial for many months now, and at last we have secured funding from sources including Allicin International.
“MRSA is causing a genuine crisis in our hospital system in Britain and worldwide. Antibiotics are increasingly ineffective, but we do have a powerful natural ally. Plant compounds have evolved over millions of years as chemical defence agents against infection. Garlic has been used in medicine for centuries, and it should be no surprise that it is effective against this very modern infection.”
The research on the laboratory effects of allicin on GISA was presented in part at the Institute of Biomedical Scientists congress in Birmingham, October 2003, and is being prepared for publication in the Journal of Biomedical Science, to appear in the New Year. A full clinical study involving the use of allicin to reduce nasal carriage in healthy volunteers, including in hospitals in London and South East England, is underway and initial results are due to be published in summer 2004.
Case Study: Deborah’s story Deborah Brown (34), a probation service officer who lives in Rainham, Kent, contracted MRSA after a major spinal operation in November 2000.
The painful wounds on her spine failed to heal despite constant applications of both oral antibiotics and creams, which also failed to reduce the levels of MRSA in her tissue.
In December 2002, Deborah’s mother Pauline contacted Dr Cutler after seeing an item on TV about MRSA and received a course of Allimax cream and capsules by post. Within two months, the MRSA had mostly cleared from Deborah’s tissues and the wounds had begun to heal, allowing an operation to remove her spinal supports to be carried out in June 2003. Deborah said: “The effect of the treatment was dramatic - I am making a good recovery now – but it was really awful at the time. Having weeping wounds on my back that never healed for two years was incredibly painful, and I became increasingly depressed as the MRSA didn’t respond to repeated courses of antibiotics. If my case helps to show that allicin works against MRSA then I am glad that something good might come of it.”
Journal of Biomedical Science (forthcoming)
For full details of Allicin treatment, click on www.allimax.com
Pictures are available from Patrick Wilson, University of East London, Phone 020 8223 2061 or 07951 797 975 or email firstname.lastname@example.org
MRSA – key facts§ Methicillin-resistant Staphylococcus aureus is a common cause of community- and hospital-acquired infection. Many strains are multiply antibiotic resistant§ Healthy people can carry MRSAs usually in the nose and pharynx. These individuals may be unaffected as Staphylococcus aureus can be part of the human bacterial population. § Problems arise when MRSA are transferred to people who have undergone surgery or have a weakened resistance to infection. MRSA become a particular problem when hospitals staff become carriers of the organism. § The organism can be easily transferred through direct contact with other carriers or infected patients or through contact with contaminated objects such as pens or bedding.
MRSA in the UK - timeline§ 1980s - MRSA emerged and became endemic in many hospitals. Vancomycin was the only antimicrobial agent with reliable effectiveness against MRSA§ 1990s - vancomycin-resistant enterococci (VRE) emerges § 1996 - the first S. aureus strain with decreased susceptibility to vancomycin, glycopeptide intermediate-resistant S. aureus (GISA) reported in Japan§ 1997 - the first GISA strains were reported in the United States§ 1999 - GISA reported in Scotland§ 2002 - a patient in Monklands Hospital contracted an MRSA which persisted and developed drug resistance to glycopeptides (vancomycin MIC 8ug/l). The patient later died from endocarditis and metastatic lung abscesses§ 2003 - GISAs now resistant to all antibiotics including vancomycin
University of East London Our vision is to achieve recognition, both nationally and internationally, as a successful and inclusive regional university proud of our diversity, committed to new modes of learning which focus on students and enhance their employability, and renowned for our contribution to social, cultural and economic development, especially through our research and scholarship.
This item has been withdrawn. Registered users can contact the publishing organisation for further details by logging in